Tarsus PharmaceuticalsTARS
About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Employees: 323
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
122% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $627K
6% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 33
0% more capital invested
Capital invested by funds: $2.23B [Q4 2024] → $2.23B (+$4.67M) [Q1 2025]
0.81% less ownership
Funds ownership: 105.29% [Q4 2024] → 104.48% (-0.81%) [Q1 2025]
2% less funds holding
Funds holding: 192 [Q4 2024] → 188 (-4) [Q1 2025]
11% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 71
22% less funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Goldman Sachs Andrea Tan | 13%upside $51 | Neutral Maintained | 5 May 2025 |
Guggenheim Eddie Hickman | 87%upside $84 | Buy Maintained | 2 May 2025 |
Jefferies Anthony Petrone | 29%upside $58 | Buy Maintained | 6 Mar 2025 |
HC Wainwright & Co. Oren Livnat | 62%upside $73 | Buy Reiterated | 26 Feb 2025 |
Barclays Balaji Prasad | 33%upside $60 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 10 articles about TARS published over the past 30 days









